Analgesic Treatment Mediated by Arcoxia (0663-093)

NCT ID: NCT00380523

Last Updated: 2022-02-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 237 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-04-30
• Study Completion Date: 2005-05-31

Brief Summary

Allow physicians to test the efficacy of arcoxia in patients with acute pain.

Conditions

Pain

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnosis of acute pain susceptible of pharmacological treatment
• Greater than 18 years of age
• Voluntary acceptance to participate in the study and signature of the informed consent form

Exclusion Criteria

• Allergy to etoricoxib or any of its components
• Less than 18 years old
• Patient is taking anticoagulants
• Patient that already has taken any drug as analgesic

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Organon and Co

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Monitor

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Other Identifiers

2006_034

Identifier Type: -

Identifier Source: secondary_id

0663-093

Identifier Type: -

Identifier Source: org_study_id